Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy

PLoS Medicine

Volumn 6, Issue 5, 2009, Pages

  Wu, Joseph T ^a   Leung, Gabriel M ^a   Lipsitch, Marc ^b   Cooper, Ben S ^c   Riley, Steven ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVALENCE;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; MODELS, THEORETICAL;

EID: 66349121943     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000085     Document Type: Article

References (40)

1. Colizza V, Barrat A, Barthelemy M, Valleron AJ, Vespignani A (2007) Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions. PLoS Med 4: e13. doi:10.1371/journal.pmed.0040013. (Pubitemid 46191825)
2. Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, et al. (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437: 209-214. (Pubitemid 41294478)
3. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, et al. (2006) Strategies for mitigating an influenza pandemic. Nature 442: 448-452. (Pubitemid 44264793)
4. Germann TC, Kadau K, Longini IM Jr, Macken CA (2006) Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A 103: 5935-5940.
5. Lipsitch M, Cohen T, Murray M, Levin BR (2007) Antiviral resistance and the control of pandemic influenza. PLoS Med 4: e15. doi:10.1371/journal.pmed. 0040015.
6. Longini IM Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, et al. (2005) Containing pandemic influenza at the source. Science 309: 1083-1087. (Pubitemid 41134467)
7. Wu JT, Riley S, Fraser C, Leung GM (2006) Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Med 3: e361. doi:10.1371/journal.pmed.0030361. (Pubitemid 44455264)
8. Meijer A, Lackenby A, Hay A, Zambon M (2007) Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. Euro Surveill 12: E3-4.
9. Ong AK, Hayden FG (2007) John F. Enders lecture 2006: antivirals for influenza. J Infect Dis 196: 181-190. (Pubitemid 47047456)
10. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, et al. (2004) Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 190: 1627-1630. (Pubitemid 39411012)
11. Ferguson NM, Mallett S, Jackson H, Roberts N, Ward P (2003) A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother 51: 977-990. (Pubitemid 36503432)
12. [No authors listed] (2008) Update: influenza activity-United States, September 30, 2007-February 9, 2008. MMWR Morb Mortal Wkly Rep 57: 179-183.
13. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, et al. (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. Jama 301: 1034-1041.
14. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-2008. Emerg Infect Dis 15: 155-162.
15. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, et al. (2009) Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 Season. Emerg Infect Dis 15: 552-560.
16. Moscona A (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360: 953-956.
17. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten R, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide in 2004-2008. Antimicrob Agents Chemother 52: 3284-3292.
18. Tamura D, Mitamura K, Yamazaki M, Fujino M, Nirasawa M, et al. (2009) Oseltamivir-resistant influenza a viruses circulating in Japan. J Clin Microbiol, E-pub ahead of print. doi:10.1128/JCM.02396-08.
19. Alexander ME, Bowman CS, Feng Z, Gardam M, Moghadas SM, et al. (2007) Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proc Biol Sci 274: 1675-1684. (Pubitemid 47356117)
20. Regoes RR, Bonhoeffer S (2006) Emergence of drug-resistant influenza virus: population dynamical considerations. Science 312: 389-391.
21. Stilianakis NI, Perelson AS, Hayden FG (1998) Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 177: 863-873. (Pubitemid 28155137)
22. Mills CE, Robins JM, Lipsitch M (2004) Transmissibility of 1918 pandemic influenza. Nature 432: 904-906. (Pubitemid 40037151)
23. Halloran ME, Hayden FG, Yang Y, Longini IM Jr, Monto AS (2007) Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol 165: 212-221. (Pubitemid 46096383)
24. Yang Y, Longini IM, Halloran ME (2006) Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups. J R Stat Soc Ser C Appl Stat 55: 317-330.
25. Handel A, Longini IM Jr, Antia R (2007) What is the best control strategy for multiple infectious disease outbreaks? Proc Biol Sci 274: 833-837.
26. Hayden F (2009) Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48 Suppl 1: S3-13.
27. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70: 121-131. (Pubitemid 43765615)
28. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12: 363-370. (Pubitemid 46787981)
29. Masihi KN, Schweiger B, Finsterbusch T, Hengel H (2007) Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice. J Chemother 19: 295-303. (Pubitemid 47075125)
30. Cooper BS, Pitman RJ, Edmunds WJ, Gay NJ (2006) Delaying the international spread of pandemic influenza. PLoS Med 3: e212. doi:10.1371/journal.pmed.0030212.
31. Hayden FG, Douglas RG Jr, Simons R (1980) Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 18: 536-541. (Pubitemid 11224626)
32. Ison MG, Gnann JW Jr, Nagy-Agren S, Treannor J, Paya C, et al. (2003) Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 8: 183-190. (Pubitemid 36960891)
33. Kawai N, Ikematsu H, Iwaki N, Maeda T, Kanazawa H, et al. (2008) A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infect 56: 51-57. (Pubitemid 350258321)
34. Kawai N, Ikematsu H, Iwaki N, Tanaka O, Yamanishi Y, et al. (2007) Zanamivir treatment is equally effective for both influenza A and influenza B. Clin Infect Dis 44: 1666-11666 (Pubitemid 46871519)
35. Collins PJ, Haire LF, Lin YP, Liu JF, Russell RJ, et al. (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453: 1258-U1261.
36. Zurcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, et al. (2006) Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother 58: 723-732. (Pubitemid 44390944)
37. Ferraris O, Lina B (2008) Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 41: 13-19. (Pubitemid 350298978)
38. Reece PA (2007) Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 79: 1577-1586. (Pubitemid 47328747)
39. Ives JAL, Carr JA, Mendel DB, Tai CY, Lambkin R, et al. (2002) The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Research 55: 307-317. (Pubitemid 34718130)
40. Viboud C, Bjornstad ON, Smith DL, Simonsen L, Miller MA, et al. (2006) Synchrony, waves, and spatial hierarchies in the spread of influenza. Science 312: 447-451.